Enveda Biosciences Bags $55M for AI-Driven Drug Discovery

Enveda Biosciences, a biotechnology company leveraging artificial intelligence to develop new medicines, has secured $55 million in funding to enhance its drug discovery platform, focusing on small molecules and advancing clinical trials.

Meanwhile, Microsoft, one of the primary investors, will provide Enveda with capital and cloud computing credits. This funding round also saw participation from Premji Invest, Lingotto Investment Fund, The Nature Conservancy, and existing Enveda backers.

Enveda Biosciences, based in Boulder, Colorado, is pioneering a platform that uses AI to expedite drug discovery by exploring the planet’s “dark chemical space.” The platform features a database of small molecules active ingredients in about 90 percent of pharmaceutical drugs.

The database emphasizes molecules found in plants, currently cataloging data on 38,000 medicinal plants linked to approximately 12,000 diseases and symptoms.

“The investors who joined in this round recognize our rapid progress and our expansive potential and vision. Combined with our deep bench of top-tier investors, we are in an ideal position to advance our novel medicines into the clinic and bring hope to waiting patients,” said Viswa Colluru, CEO and Founder of Enveda.

Advanced Techniques and AI Integration

Enveda’s researchers utilize tandem mass spectrometry to gather data on promising compounds. This technique involves projecting electrons onto a material to create ions, which are then analyzed for unknown compounds.

Enveda’s AI model, based on the Transformer architecture, automates converting mass-spectrometry readings into structural formulas. This AI-driven approach significantly speeds up parts of the drug discovery process.

The small molecules database is accessible through a Google-like interface, allowing scientists to find compounds with specific chemical properties using natural descriptions. For example, researchers can search for compounds involved in photosynthesis that fall below a certain mass threshold.

We are excited by Enveda’s potential to deliver new, safe and efficacious treatments for complex conditions, pushing the boundaries of AI and ML in life sciences. Enveda has made significant progress in creating a platform that learns from the diversity in natural chemistry and can translate this knowledge to develop novel therapeutics,” said Sandesh Patnam, Managing Partner at Premji Invest.

Funding to Drive Innovation and Clinical Trials

The recent funding will enhance Enveda’s platform and support two drug development programs targeting skin conditions and bowel disease. The company plans to advance these programs to clinical trials by late 2024 and early 2025.

Enveda’s lead program for atopic dermatitis involves a novel oral anti-inflammatory agent showing remarkable efficacy in preclinical studies. Another program focuses on a first-in-class anti-inflammatory for inflammatory bowel disease, inhibiting multiple cytokine signaling cascades in the gut.

Founded in 2019, Enveda aims to understand and utilize the chemistry of life to address today’s clinical needs. Enveda Biosciences is creating a unique library of life by building a comprehensive chemical biodiversity database. This funding round marks a significant milestone in Enveda’s mission to revolutionize drug discovery using AI.

Enveda holds immense potential for long-term, unrestricted growth due to the broad applicability of its technology across various challenging issues impacting human health and environmental well-being. Morgan Samet, Partner and Co-Head- Lingotto Investment, said that their innovative solutions’ wide range of applications positions the company favorably for sustained expansion.

Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.

We Recommend: